Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway
about
Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiationIdentification of Baicalin as an immunoregulatory compound by controlling T(H)17 cell differentiationPathogenesis of kidney disease in systemic lupus erythematosus.Lupus pathobiology based on genomics.Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and futureSystems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.T-cell and B-cell signaling biomarkers and treatment targets in lupus.Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosusClinical associations of serum interleukin-17 in systemic lupus erythematosus.Requirements for innate immune pathways in environmentally induced autoimmunity.B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.T cell and dendritic cell abnormalities synergize to expand pro-inflammatory T cell subsets leading to fatal autoimmunity in B6.NZBc1 lupus-prone miceThe role of cytokine in the lupus nephritis.The current concept of T (h) 17 cells and their expanding role in systemic lupus erythematosus.Cytokine disturbances in systemic lupus erythematosus.The discovery and development of belimumab: the anti-BLyS-lupus connectionDispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.Transcriptional analysis of infiltrating T cells in kidney ischemia-reperfusion injury reveals a pathophysiological role for CCR5.Vitamin A improve Th17 and Treg regulation in systemic lupus erythematosus.Cutting edge: Leptin-induced RORγt expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus.Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.Suppressive oligodeoxynucleotides promote the development of Th17 cells.Immune and inflammatory role in renal disease.Th1 and Th17 cells induce proliferative glomerulonephritis.Interleukin-17 and systemic lupus erythematosus: current concepts.The role of dendritic cells in the pathogenesis of systemic lupus erythematosus.The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus.Future prospects in biologic therapy for systemic lupus erythematosus.Safety of off-label biologicals in systemic lupus erythematosus.MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus.Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis.Interluekin-17A (IL17A).IL-17 mediates neutrophil infiltration and renal fibrosis following recovery from ischemia reperfusion: compensatory role of natural killer cells in athymic rats.Haploinsufficiency of NADPH Oxidase Subunit Neutrophil Cytosolic Factor 2 Is Sufficient to Accelerate Full-Blown Lupus in NZM 2328 Mice.The potential protective role of hepatitis B virus infection in pristane-induced lupus in mice.Phage display-derived human antibodies in clinical development and therapyAnti-tumor necrosis factor α treatment of interferon-α-induced murine lupus nephritis reduces the renal macrophage response but does not alter glomerular immune complex formation.Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity.Detection of dynamic frequencies of Th17 cells and their associations with clinical parameters in patients with systemic lupus erythematosus receiving standard therapy.
P2860
Q24300244-4BF1BCAC-CB46-4D27-AF91-F77AC54712EFQ28477172-1D2141A9-3085-466E-9609-E8C8444919D4Q30434907-67528F6D-6B06-4350-9016-EF3DA7C42924Q33364409-4EFF722D-9AF6-4879-A59D-882DA498FE8FQ33601679-34E68B50-D3B2-4843-AAD3-D18E47441A75Q33608479-A503B1EB-3219-4B55-871C-0BF60985B4A3Q33718893-99E79C28-8692-4562-9586-43C0E1343014Q33923351-317585BA-9EF3-4F79-B9FD-53C5FFE43177Q34365880-EE3B1162-F230-4B05-B327-56804028A3C2Q34655526-22E367CE-6EE7-4F08-94BA-6425C8336E1BQ34781487-D39F5450-8F29-4D19-A160-06A4DBCCF822Q35000797-EE887F98-36F1-4C82-8629-7955461DB39CQ35418333-653428E9-546F-4D34-A5BF-C07C8A7D14B6Q35579076-FCB7917B-AD9D-4A29-B9C7-8C934E28E58FQ35617573-F95C25FE-9490-4E49-8D41-43D86489072EQ35691272-E6E68FE2-32C3-41F9-90C4-FA0067CE844FQ35798968-9EDAC1B7-53F6-4F93-BA72-A4008135B1F3Q35849486-3F0D8FB1-9654-4856-A06A-B5FFD2170334Q35916695-2A1E12AB-2C07-4B4B-9A1E-07FC772456E3Q36718109-674BFB2F-0D7B-440F-970F-5F800DDB5311Q36745567-CB39F7F6-0498-4E74-9835-18DB47ED71E5Q36976397-76390634-D4C6-4D2E-A11B-EF4D98987126Q37243199-584105EF-BC7B-4036-B856-014CE6E232B4Q37477762-A0703FD1-4C8D-41F0-9CAE-9A7E1E664AF5Q37552021-309272CF-2105-4FB6-9007-40CB8C86D2DFQ37737799-98CF4BEA-6AD8-4BEB-925E-899AD8CDF8BAQ37852758-918CB236-F9ED-4B0D-A1FA-1461F60C4EA6Q37864851-8EC213CD-048D-4BFD-91F5-601FE66649F5Q38135706-7EFF4581-0DA0-45C6-A249-71577717AFE1Q38284560-163D05A8-6D8C-42B0-99D0-08B6288E5A68Q38655827-D1AE0CEB-581B-4B53-A2BF-A4F8BE9BB2F5Q39101016-491A4357-13F9-4612-8403-4C1DC520D8DCQ39103136-D8FF84DB-2E0E-48AD-8B1F-D5E5EDFD2A02Q39182623-2AA076CE-BC28-42DB-8503-0E94BFE54106Q40226730-220AC6C0-AD59-468C-95BE-B5737F9DAB5FQ40695129-EF886C07-6971-4936-9C4E-4111A527ACDAQ41416393-3B1CA8DF-9218-4A6A-99B7-92B85417E4F4Q41837557-2C5D054B-5162-4440-A04F-354A8BB02743Q41840662-7C0ACD76-D974-4439-91B7-417462CED5EEQ41921501-798F41A6-3980-45DE-9ECC-7F3ED92EF098
P2860
Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Accelerated pathological and c ...... via a Th17-associated pathway
@ast
Accelerated pathological and c ...... via a Th17-associated pathway
@en
Accelerated pathological and c ...... via a Th17-associated pathway
@nl
type
label
Accelerated pathological and c ...... via a Th17-associated pathway
@ast
Accelerated pathological and c ...... via a Th17-associated pathway
@en
Accelerated pathological and c ...... via a Th17-associated pathway
@nl
prefLabel
Accelerated pathological and c ...... via a Th17-associated pathway
@ast
Accelerated pathological and c ...... via a Th17-associated pathway
@en
Accelerated pathological and c ...... via a Th17-associated pathway
@nl
P2093
P2860
P356
P1476
Accelerated pathological and c ...... via a Th17-associated pathway
@en
P2093
Chaim O Jacob
Chaim Putterman
Haitao Yang
Hua-Xin Gao
Juhua Wang
Luminita Pricop
Michael N Koss
Noam Jacob
Song Guo Zheng
William Stohl
P2860
P304
P356
10.4049/JIMMUNOL.0802948
P407
P577
2009-02-01T00:00:00Z